Altimmune Inc (ALT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Altimmune Inc (ALT) has a cash flow conversion efficiency ratio of -0.086x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.45 Million) by net assets ($224.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Altimmune Inc to measure how many days the company can operate on defensive assets alone.
Altimmune Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Altimmune Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Altimmune Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Altimmune Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jindal Worldwide Limited
NSE:JINDWORLD
|
0.100x |
|
Shanghai Xin Nanyang Co Ltd
SHG:600661
|
-0.043x |
|
Race Oncology Ltd
AU:RAC
|
-0.093x |
|
Cartesian Growth Corporation III Class A Ordinary Shares
NASDAQ:CGCT
|
-0.001x |
|
Pollard Banknote Limited
TO:PBL
|
0.007x |
|
Jiangxi Everbright Measurement Cont
SHE:300906
|
0.007x |
|
Indo Thai Securities Limited
NSE:INDOTHAI
|
0.032x |
|
Meteoric Resources NL
AU:MEI
|
-2.091x |
Annual Cash Flow Conversion Efficiency for Altimmune Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Altimmune Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see Altimmune Inc (ALT) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $224.89 Million | $-67.53 Million | -0.300x | +53.55% |
| 2024-12-31 | $123.51 Million | $-79.85 Million | -0.647x | -65.53% |
| 2023-12-31 | $194.10 Million | $-75.81 Million | -0.391x | -15.63% |
| 2022-12-31 | $185.29 Million | $-62.59 Million | -0.338x | +14.03% |
| 2021-12-31 | $199.13 Million | $-78.24 Million | -0.393x | -157.70% |
| 2020-12-31 | $225.88 Million | $-34.44 Million | -0.152x | +27.72% |
| 2019-12-31 | $45.52 Million | $-9.60 Million | -0.211x | -8.54% |
| 2018-12-31 | $48.31 Million | $-9.39 Million | -0.194x | +53.20% |
| 2017-12-31 | $48.68 Million | $-20.21 Million | -0.415x | -104.01% |
| 2016-12-31 | $19.46 Million | $201.51 Million | 10.355x | +5461.03% |
| 2015-12-31 | $16.65 Million | $-3.22 Million | -0.193x | +58.34% |
| 2014-12-31 | $18.27 Million | $-8.47 Million | -0.464x | +52.54% |
| 2013-12-31 | $7.34 Million | $-7.17 Million | -0.977x | -391.08% |
| 2012-12-31 | $11.67 Million | $-2.32 Million | -0.199x | +59.61% |
| 2011-12-31 | $15.85 Million | $-7.81 Million | -0.493x | +59.53% |
| 2010-12-31 | $12.21 Million | $-14.86 Million | -1.217x | +91.85% |
| 2009-12-31 | $1.88 Million | $-28.15 Million | -14.936x | -2046.03% |
| 2008-12-31 | $18.96 Million | $-13.20 Million | -0.696x | -107.07% |
| 2007-12-31 | $40.57 Million | $-13.64 Million | -0.336x | -1355.97% |
| 2006-12-31 | $57.11 Million | $1.53 Million | 0.027x | +236.37% |
| 2005-12-31 | $69.68 Million | $554.33K | 0.008x | -- |
About Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.